{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:29:49Z","timestamp":1791214189609,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.cgh.2008.03.014","type":"journal-article","created":{"date-parts":[[2008,6,11]],"date-time":"2008-06-11T06:18:03Z","timestamp":1213165083000},"page":"644-653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":473,"title":["Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials"],"prefix":"10.1016","volume":"6","author":[{"given":"Laurent","family":"Peyrin\u2013Biroulet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Deltenre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"de Suray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Branche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2013Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2008.03.014_bib1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease: Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2008.03.014_bib2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2008.03.014_bib3","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2008.03.014_bib4","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2008.03.014_bib5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2008.03.014_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2008.03.014_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2008.03.014_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2008.03.014_bib9","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2008.03.014_bib10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2008.03.014_bib11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2008.03.014_bib12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2008.03.014_bib13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2036.2005.02336.x","article-title":"A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease","volume":"21","author":"Feagan","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2008.03.014_bib14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2036.2006.02791.x","article-title":"CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Feagan","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2008.03.014_bib15","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.cgh.2006.04.022","article-title":"Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"4","author":"Rutgeerts","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2008.03.014_bib16","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1053\/gast.2001.24042","article-title":"An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial","volume":"120","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2008.03.014_bib17","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/gut.2003.035253","article-title":"CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial","volume":"53","author":"Sandborn","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2008.03.014_bib18","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2008.03.014_bib19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(97)80083-9","article-title":"Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease","volume":"349","author":"Stack","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2008.03.014_bib20","article-title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease","author":"Akobeng","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2008.03.014_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.biopha.2006.06.022","article-title":"Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease?","volume":"61","author":"Rahimi","year":"2007","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.cgh.2008.03.014_bib22","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2008.03.014_bib23","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2004.01.024","article-title":"A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease","volume":"126","author":"Su","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2008.03.014_bib24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods for combining randomized clinical trials: strengths and limitations","volume":"6","author":"Demets","year":"1987","journal-title":"Stat Med"},{"key":"10.1016\/j.cgh.2008.03.014_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.cgh.2008.03.014_bib26","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.cgh.2008.03.014_bib27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1016\/j.cgh.2008.03.014_bib28","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","article-title":"Confidence intervals for the number needed to treat","volume":"317","author":"Altman","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2008.03.014_bib29","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1365-2036.2004.02285.x","article-title":"Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study","volume":"20","author":"Winter","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2008.03.014_bib30","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial","volume":"130","author":"Lemann","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2008.03.014_bib31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2036.2003.01414.x","article-title":"Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study","volume":"17","author":"Rutgeerts","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.cgh.2008.03.014_bib32","first-page":"A108","article-title":"The ideal management of Crohn's disease: Top down versus step up strategies, a randomized controlled trial","volume":"130","author":"Hommes","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2008.03.014_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jahad","year":"1996","journal-title":"Controlled Clin Trials"},{"key":"10.1016\/j.cgh.2008.03.014_bib34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2008.03.014_bib35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/gut.2005.075937","article-title":"Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study","volume":"55","author":"Biancone","year":"2006","journal-title":"Gut"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356508002917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356508002917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:01:51Z","timestamp":1761541311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356508002917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S1542356508002917"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2008.03.014","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2008.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}